215 Diagnostic utility of molecular and imaging biomarkers 2 malignant histology, ni included indeterminate cytology US features analyzed malignant PTC FVPTC FTC FTC-OV MTC other n.s. follicular neoplasm SN, HY, SZ 18% 11 1 9 suspicious for follicular or Hürthle cell neoplasm SS 25% 29 follicular neoplasm IV 12% 2 5 3 follicular neoplasm other 21% 1 1 1 4 hypercellular follicular, oxyphilic or suspicious cytology SO 26% 4 4 2 1 follicular or Hürthle cell neoplasm, or indeterminate SN 19% 4 8 36 11 4 follicular neoplasm SN, SO, HY, SZ, MI 27% 14 6 6 follicular or Hürthle cell neoplasm SN, SZ 43% 3 3 follicular lesion or neoplasm SS 15% 46 indeterminate HY, AH, IV, MI 22% 9 17 5 follicular neoplasm other 24% 3 12 8 1 indeterminate SN, SO, HY, SZ, TW, IM, MI, MA 19% 1 4 10 1 3 Thy3 SO, NZ, IV, MI, MA 29% 8 6 2 1 Bethesda III other 47% 18 1 1 follicular or Hürthle cell neoplasm other 3% 1 indeterminate SN, SO, HY, SZ, TW, AH, IM, IV, MI, MA 35% 2 32 2 Bethesda III or IV other 25% 9 6 4 1 Hürthle cell lesion (>75% Hürthle cells) SN, SZ 30% 15 6 Thy3 HY, IM, IV, MI 29% 34 6 Bethesda III+IV, and indeterminate n.o.s. SO, HY, AH, IM, IV, MI 39% 7 3 12 Bethesda III SO, SS, MA 49% 68 Bethesda III SO, HY, SZ, TW, IM, MI, MA 55% 86 Bethesda III other 55% 89 2 Hürthle cell lesion (>75% Hürthle cells) SO, HY, SZ, TW, IM, MA 15% 4 3 3 1 Bethesda IV SO, HY, SZ, AH, IM, MA 48% 31 16 indeterminate or follicular lesion HY, AH, IV, MI 25% 1 2 1 Hürthle cell cytology SO, HY, SZ, IM, MI 35% 21 2 3 2 1 follicular pattern SN, SO, HY, AH, IM, IV, MI, other 14% 14 Bethesda III or IV TI 26% 9 Bethesda III or IV SO, HY, SZ, IM, MI 36% 22 1 2 3 Bethesda III AUS SO, HY, AH, IM, IV, MA 30% 81 Thy3 HY, IM, IV, MI 35% 35 32 18 2 Thy3F HY, SZ, TW, IM, IV, MI, TI 24% 15 16 1 3
RkJQdWJsaXNoZXIy MTk4NDMw